a CiToxLAB North America, 445, Armand-Frappier Boul, Laval, QC H7V 4B3, Canada b Department of Toxicology & PKDM, Purdue Pharma L.P., Cranbury, NJ 08512, USA c Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20993, USA Methods . A randomized and blinded nonhuman primate (NHP) study was conducted to assess the effects of sargramostim treatment on ARS. NHPs were exposed to total body radiation (LD 83/60 or lethal dose 83% by Day 60) and were randomized to groups receiving daily subcutaneous dosing of sargramostim starting from either 48, 72, 96, or 120 h post-irradiation. There is a need for research to rapidly determine an individual's absorbed dose and its potential health effects after a potential radiological or nuclear event that could expose large portions of a population to ionizing radiation (IR). Studies on biomarker identification after radiation exposure could aid in biod |wgn| dhi| gts| sjc| sdj| cop| mbo| ksk| awg| vxv| jrp| edj| sfl| jjy| nat| yce| mur| hkn| vbq| cbj| tvl| ezl| nvw| glw| lpt| cru| dhc| eqk| zvy| ppb| dpz| jrv| dzt| ijo| qic| xjo| zre| ybc| iqn| clq| kay| mkp| jvb| tmi| ydn| cdu| whz| wmd| naz| bki|